publication venue for
- EDITOR SPOTLIGHT: Interview with Cholinergic Mechanisms Special Issue Guest Editor Hermona Soreq.. 168:331-333. 2024
- Recent advances in cholinergic mechanisms: A preface for the ISCM2022 special issue.. 168:334-338. 2023
- Novel single-nucleus transcriptomics unravels developmental and functionally controlled principles of mammalian neuromuscular junctions.. 168:339-341. 2023
- Recent advances in cholinergic mechanisms as reactions to toxicity, stress, and neuroimmune insults.. 168:355-369. 2023
- Cerebrospinal fluid and blood profiles of transfer RNA fragments show age, sex, and Parkinson's disease-related changes.. 164:671-683. 2022
- Preface: Cholinergic mechanisms: This is the Preface for the special issue "Cholinergic Mechanisms".. 158:1212-1216. 2021
- Inhibition of CD38 and supplementation of nicotinamide riboside ameliorate lipopolysaccharide-induced microglial and astrocytic neuroinflammation by increasing NAD.. 158:311-327. 2021
- Regulators of cholinergic signaling in disorders of the central nervous system.. 158:1425-1438. 2021
- The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases.. 152:235-251. 2019
- Modulation of hippocampal neuronal resilience during aging by the Hsp70/Hsp90 co-chaperone STI1.. 153:727-758. 2019
- Alterations in brain TREM2 and Amyloid-β levels are associated with neurocognitive impairment in HIV-infected persons on antiretroviral therapy.. 147:784-802. 2018
- Alexander George Karczmar (1917-2017).. 143:609-611. 2017
- Personalized genetics of the cholinergic blockade of neuroinflammation.. 142 Suppl 2:178-187. 2017
- Targeting innate immunity for neurodegenerative disorders of the central nervous system.. 138:653-93. 2016
- Proteolysis of α-synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology.. 140:662-678. 2016
- Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies.. 139 Suppl 2:224-236. 2016
- LRRK2 pathobiology in Parkinson's disease - virtual inclusion.. 75-76. 2016
- Purines: forgotten mediators in traumatic brain injury.. 137:142-53. 2016
- Estrogen receptor beta signaling alters cellular inflammasomes activity after global cerebral ischemia in reproductively senescence female rats.. 136:492-6. 2015
- Exosome-mediated inflammasome signaling after central nervous system injury.. 136 Suppl 1:39-48. 2015
- E2F1 in neurons is cleaved by calpain in an NMDA receptor-dependent manner in a model of HIV-induced neurotoxicity.. 132:742-55. 2014
- LRRK2 pathobiology in Parkinson's disease.. 131:554-65. 2014
- Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.. 131:859-67. 2014
- Protection of dopaminergic cells by urate requires its accumulation in astrocytes.. 123:172-81. 2012
- NMDA receptor modulation by the neuropeptide apelin: implications for excitotoxic injury.. 118:1113-23. 2011
- Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex.. 115:1608-20. 2010
- Contributions of poly(ADP-ribose) polymerase-1 and -2 to nuclear translocation of apoptosis-inducing factor and injury from focal cerebral ischemia.. 113:1012-22. 2010
- Calpain activation is not required for AIF translocation in PARP-1-dependent cell death (parthanatos).. 110:687-96. 2009
- A novel reciprocal and biphasic relationship between membrane cholesterol and beta-secretase activity in SH-SY5Y cells and in human platelets.. 108:341-9. 2009
- Cellular calcium deficiency plays a role in neuronal death caused by proteasome inhibitors.. 109:1225-36. 2009
- Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.. 111:1478-89. 2009
- Glutamate mobilizes [Zn2+] through Ca2+ -dependent reactive oxygen species accumulation.. 106:2184-93. 2008
- Parkin mediates the degradation-independent ubiquitination of Hsp70.. 105:1806-19. 2008
- Apelin, an endogenous neuronal peptide, protects hippocampal neurons against excitotoxic injury.. 102:1905-1917. 2007
- Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus.. 104:279-86. 2007
- Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain.. 100:368-81. 2006
- Disease modifying therapy for AD?. 99:689-707. 2006
- Developmental and cell-selective variations in N-methyl-D-aspartate receptor degradation by calpain.. 99:206-17. 2006
- Modulated splicing-associated gene expression in P19 cells expressing distinct acetylcholinesterase splice variants.. 24-34. 2006
- C-terminal PAL motif of presenilin and presenilin homologues required for normal active site conformation.. 96:218-27. 2005
- Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42.. 96:355-65. 2005
- Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons.. 94:1040-53. 2005
- Prostaglandin H(2)-derived adducts of proteins correlate with Alzheimer's disease severity.. 94:1140-5. 2005
- Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations.. 93:422-31. 2005
- Inherited and acquired interactions between ACHE and PON1 polymorphisms modulate plasma acetylcholinesterase and paraoxonase activities.. 92:1216-27. 2005
- Prostaglandin D2 mediates neuronal protection via the DP1 receptor.. 92:477-86. 2005
- Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia.. 95:919-29. 2005
- Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartate effects.. 95:1188-200. 2005
- PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury.. 90:1068-75. 2004
- Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits.. 90:1011-8. 2004
- Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage.. 88:538-44. 2004
- A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization.. 87:1558-67. 2003
- Androgens modulate beta-amyloid levels in male rat brain.. 87:1052-5. 2003
- Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro.. 86:836-47. 2003
- A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism.. 83:186-92. 2002
- Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease.. 81:229-36. 2002
- Reduction of functional N-methyl-D-aspartate receptors in neurons by RNase P-mediated cleavage of the NR1 mRNA.. 76:1386-94. 2001
- Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potential vector for delivering heterologous proteins to neurons.. 74:2528-36. 2000
- Novel effects of FCCP [carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone] on amyloid precursor protein processing.. 72:1457-65. 1999
- Contrasting calcium dependencies of SAPK and ERK activations by glutamate in cultured striatal neurons.. 72:2248-55. 1999
- Leukemia inhibitory factor and ciliary neurotrophic factor increase activated Ras in a neuroblastoma cell line and in sympathetic neuron cultures.. 63:1246-54. 1994
- Decline in response to nicotine in aged rat striatum: correlation with a decrease in a subpopulation of nicotinic receptors.. 61:2225-32. 1993
- Effects of peptides of the secretin-glucagon family and cyclic nucleotides on tyrosine hydroxylase activity in sympathetic nerve endings.. 56:400-6. 1991
- Autoradiographic evidence of [3H]SCH 23390 binding sites in human prefrontal cortex (Brodmann's area 9).. 49:789-96. 1987